Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merz Pharmaceuticals GmbH

https://www.merz.com/

Latest From Merz Pharmaceuticals GmbH

Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund

Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.

Financing Innovation

Sawai Ends American Dream With Upsher-Smith Sale

Japanese generics giant Sawai is pulling out of the US market, agreeing a deal to divest its Upsher-Smith business to Taiwan’s Bora Pharmaceuticals in a deal worth a little over $200m. As Sawai explained its rationale for the move, Bora pointed to “significant opportunities” for its TWi commercial prescription unit arising from the acquisition.

Deals M & A

Sawai Ends American Dream With Upsher-Smith Sale

Japanese generics giant Sawai is pulling out of the US market, agreeing a deal to divest its Upsher-Smith business to Taiwan’s Bora Pharmaceuticals in a deal worth a little over $200m. As Sawai explained its rationale for the move, Bora pointed to “significant opportunities” for its TWi commercial prescription unit arising from the acquisition.

Deals M & A

Isotretinoin REMS Modifications Show How Advisory Panel Can Push FDA To Change Its Mind

US FDA makes five changes to ease burden of risk management program for acne drug – going further than the agency initially seemed comfortable with in March, though not always in line with what the generic sponsors were seeking.

Post Market Regulation & Studies Drug Safety
See All

Company Information

  • Industry
  • Diversified
  • Other Names / Subsidiaries
    • BioteCon Therapeutics GmbH
    • Cabochon Aesthetics, Inc.
    • ON Light Sciences, Inc.
    • Ulthera, Inc.
    • Merz Pharmaceuticals GmbH
    • Merz Pharma France
    • Merz North America, Inc.
    • Merz Pharma (Schweiz) Ag
    • Merz Pharma GmbH
UsernamePublicRestriction

Register